Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1

Nature Medicine

Volumn 24, Issue 6, 2018, Pages 857-867

  Xu, Kai ^a   Acharya, Priyamvada ^a,b   Kong, Rui ^a   Cheng, Cheng ^a   Chuang, Gwo Yu ^a   Liu, Kevin ^a   Louder, Mark K ^a   O'Dell, Sijy ^a   Rawi, Reda ^a   Sastry, Mallika ^a   Shen, Chen Hsiang ^a   Zhang, Baoshan ^a   Zhou, Tongqing ^a   Asokan, Mangaiarkarasi ^a   Bailer, Robert T ^a   Chambers, Michael ^a   Chen, Xuejun ^a   Choi, Chang W ^a   Dandey, Venkata P ^b   Doria Rose, Nicole A ^a   Druz, Aliaksandr ^a   Eng, Edward T ^b   Farney, S Katie ^a   Foulds, Kathryn E ^a   Geng, Hui ^a   Georgiev, Ivelin S ^c   Gorman, Jason ^a   Hill, Kurt R ^a   Jafari, Alexander J ^a   Kwon, Young D ^a   Lai, Yen Ting ^a   Lemmin, Thomas ^d   McKee, Krisha ^a   Ohr, Tiffany Y ^a   Ou, Li ^a   Peng, Dongjun ^a   Rowshan, Ariana P ^a   Sheng, Zizhang ^e   Todd, John Paul ^a   Tsybovsky, Yaroslav ^f   Viox, Elise G ^a   Wang, Yiran ^a   Wei, Hui ^b   Yang, Yongping ^a   Zhou, Amy F ^a   Chen, Rui ^g   Yang, Lu ^g   Scorpio, DIana G ^a   McDermott, Adrian B ^a   Shapiro, Lawrence ^a,e   Carragher, Bridget ^b   Potter, Clinton S ^b   Mascola, John R ^a   Kwong, Peter D ^a,e   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NEW YORK STRUCTURAL BIOLOGY CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Columbia University ^*  (United States)

^f FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^g Genscript   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; EPITOPE; FUSION PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PEPTIDE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CRYOELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECT; FEMALE; IMMUNOLOGY; METABOLISM; MOLECULAR MODEL; SERODIAGNOSIS;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; FEMALE; GUINEA PIGS; HIV ANTIBODIES; HIV-1; IMMUNIZATION; MACACA MULATTA; MICE, INBRED C57BL; MODELS, MOLECULAR; NEUTRALIZATION TESTS; PEPTIDES; RECOMBINANT FUSION PROTEINS;

EID: 85047980123     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-018-0042-6     Document Type: Article

References (83)

1. Korber, B.,et al. Timing the ancestor of the HIV-1 pandemic strains. Science 288, 1789-1796 (2000).
2. UNAIDS. Global AIDS Update 2016, UNAIDS http://www. unaids. org/en/ resources/documents/2016/Global-AIDS-update-2016 (2016).
3. Hraber, P.,et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28, 163-169 (2014).
4. Mascola, J. R. & Haynes, B. F. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254, 225-244 (2013).
5. Seaman, M. S.,et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439-1452 (2010).
6. Kwong, P. D. & Mascola, J. R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37, 412-425 (2012).
7. Burton, D. R.,et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396-407 (2012).
8. Chen, L.,et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1gp120. Science 326, 1123-1127 (2009).
9. Zhou, T.,et al. Structural Repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 161, 1280-1292 (2015).
10. Scheid, J. F.,et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
11. Wu, X.,et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
12. Wu, X.,et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593-1602 (2011).
13. Doria-Rose, N. A.,et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55-62 (2014).
14. Gorman, J.,et al. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat. Struct. Mol. Biol. 23, 81-90 (2016).
15. McLellan, J. S.,et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343 (2011).
16. Walker, L. M.,et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
17. Andrabi, R.,et al. Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity 43, 959-973 (2015).
18. Briney, B. S., Willis, J. R. & Crowe, J. E. Jr. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One 7, e36750 (2012).
19. Walker, L. M.,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
20. Pejchal, R.,et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097-1103 (2011).
21. Kong, L.,et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20, 796-803 (2013).
22. Garces, F.,et al. Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity 43, 1053-1063 (2015).
23. Huang, J.,et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412 (2012).
24. Stiegler, G.,et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17, 1757-1765 (2001).
25. Muster, T.,et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68, 4031-4034 (1994).
26. Muster, T.,et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642-6647 (1993).
27. Ofek, G.,et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78, 10724-10737 (2004).
28. Ofek, G.,et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J. Virol. 84, 2955-2962 (2010).
29. Irimia, A., Sarkar, A., Stanfield, R. L. & Wilson, I. A. Crystallographic identification of lipid as an integral component of the epitope of hiv broadly neutralizing antibody 4E10. Immunity 44, 21-31 (2016).
30. Haynes, B. F., Moody, M. A., Verkoczy, L., Kelsoe, G. & Alam, S. M. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum. Antibodies 14, 59-67 (2005).
31. Kong, R.,et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 352, 828-833 (2016).
32. Carr, C. M. & Kim, P. S. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell 73, 823-832 (1993).
33. van Gils, M. J.,et al. An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat. Microbiol. 2, 16199 (2016).
34. Blattner, C.,et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40, 669-680 (2014).
35. Boudko, S. P.,et al. Crystal structure of human collagen XVIII trimerization domain: A novel collagen trimerization Fold. J. Mol. Biol. 392, 787-802 (2009).
36. Tan, K.,et al. Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J. Cell Biol. 159, 373-382 (2002).
37. Chu, R.,et al. Redesign of a four-helix bundle protein by phage display coupled with proteolysis and structural characterization by NMR and X-ray crystallography. J. Mol. Biol. 323, 253-262 (2002).
38. Mougous, J. D.,et al. A virulence locus of Pseudomonas aeruginosa encodes a protein secretion apparatus. Science 312, 1526-1530 (2006).
39. Harris, J. R. & Markl, J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron 30, 597-623 (1999).
40. Sanders, R. W.,et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP. 664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).
41. Kwon, Y. D.,et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat. Struct. Mol. Biol. 22, 522-531 (2015).
42. Trkola, A.,et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100-1108 (1996).
43. Trkola, A.,et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11, 615-622 (2005).
44. Trkola, A.,et al. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J. Virol. 82, 1591-1599 (2008).
45. Pauthner, M.,et al. Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches. Immunity 46, 1073-1088. e6 (2017).
46. Sanders, R. W.,et al. HIV-1 vaccines. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349, aac4223 (2015).
47. de Taeye, S. W.,et al. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell 163, 1702-1715 (2015).
48. Guenaga, J.,et al. Structure-guided redesign increases the propensity of HIV Env to generate highly stable soluble trimers. J. Virol. 90, 2806-2817 (2015).
49. Kong, L.,et al. Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nat. Commun. 7, 12040 (2016).
50. Zhou, T.,et al. Quantification of the impact of the HIV-1-glycan shield on antibody elicitation. Cell Rep. 19, 719-732 (2017).
51. Ekiert, D. C.,et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251 (2009).
52. Joyce, M. G.,et al. Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses. Cell 166, 609-623 (2016).
53. Furuyama, W.,et al. Discovery of an antibody for pan-Ebolavirus therapy. Sci. Rep. 6, 20514 (2016).
54. Wec, A. Z.,et al. Antibodies from a human survivor define sites of vulnerability for broad protection against Ebolaviruses. Cell 169, 878-890. e15 (2017).
55. Zhao, X.,et al. Immunization-elicited broadly protective antibody reveals Ebolavirus fusion loop as a site of vulnerability. Cell 169, 891-904. e15 (2017).
56. Hastie, K. M.,et al. Structural basis for antibody-mediated neutralization of Lassa virus. Science 356, 923-928 (2017).
57. Sok, D.,et al. Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. Nature 548, 108-111 (2017).
58. McCoy, L. E.,et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J. Exp. Med. 209, 1091-1103 (2012).
59. Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775-797 (2013).
60. Wang, F.,et al. Reshaping antibody diversity. Cell 153, 1379-1393 (2013).
61. Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152, 36-51 (2005).
62. Tang, G.,et al. EMAN2: an extensible image processing suite for electron microscopy. J. Struct. Biol. 157, 38-46 (2007).
63. Frank, J.,et al. SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J. Struct. Biol. 116, 190-199 (1996).
64. Huson, D. H.,et al. Dendroscope: an interactive viewer for large phylogenetic trees. BMC Bioinformatics 8, 460 (2007).
65. Hall, T. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium Series 41, 95-98 (1999).
66. Sarzotti-Kelsoe, M.,et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131-146 (2014).
67. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
68. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
69. Adams, P. D.,et al. Recent developments in the PHENIX software for automated crystallographic structure determination. J. Synchrotron Radiat. 11, 53-55 (2004).
70. Razinkov, I.,et al. A new method for vitrifying samples for cryoEM. J. Struct. Biol. 195, 190-198 (2016).
71. Dandey, V. P.,et al. Spotiton: New features and applications. J. Struct. Biol. 202, 161-169 (2018).
72. Wei, H.,et al. Optimizing "self-wicking" nanowire grids. J. Struct. Biol. 202, 170-174 (2018).
73. Zheng, S. Q.,et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331-332 (2017).
74. Zhang, K. Gctf: real-time CTF determination and correction. J. Struct. Biol. 193, 1-12 (2016).
75. Lander, G. C.,et al. Appion: an integrated, database-driven pipeline to facilitate EM image processing. J. Struct. Biol. 166, 95-102 (2009).
76. Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519-530 (2012).
77. Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290-296 (2017).
78. Pettersen, E. F.,et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
79. Davis, I. W., Murray, L. W., Richardson, J. S. & Richardson, D. C. MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res. 32, W615-W619 (2004).
80. Barad, B. A.,et al. EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy. Nat. Methods 12, 943-946 (2015).
81. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926-935 (1983).
82. Georgiev, I. S.,et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 340, 751-756 (2013).
83. Doria-Rose, N. A.,et al. Mapping polyclonal HIV-1 antibody responses via next-generation neutralization fingerprinting. PLoS Pathog. 13, e1006148 (2017).